BORA PHARMACEUTICALS LTD (6472) — Capital Reinvestment Ratio
BORA PHARMACEUTICALS LTD (6472) has a Capital Reinvestment Ratio of 0.37x as of March 2026, meaning it reinvests 0% of its operating cash flow (NT$568.46 Million) in capital expenditures (NT$211.08 Million). Check 6472 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
BORA PHARMACEUTICALS LTD Capital Reinvestment Ratio (2019–2025)
This chart tracks BORA PHARMACEUTICALS LTD's Capital Reinvestment Ratio across 7 annual periods. For the full cash flow conversion analysis, see BORA PHARMACEUTICALS LTD cash flow conversion.
Annual Capital Reinvestment Ratio for BORA PHARMACEUTICALS LTD (2019–2025)
Year-by-year Capital Reinvestment Ratio for BORA PHARMACEUTICALS LTD from 2019 to 2025. See how much free cash does BORA PHARMACEUTICALS LTD generate to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | NT$4.24 Billion | NT$928.67 Million | ▼ -68.7% |
| 2024 | 0.70x | NT$980.81 Million | NT$687.05 Million | ▲ +126.0% |
| 2023 | 0.31x | NT$4.61 Billion | NT$1.43 Billion | ▲ +211.2% |
| 2022 | 0.10x | NT$2.01 Billion | NT$200.22 Million | ▼ -66.1% |
| 2021 | 0.29x | NT$1.24 Billion | NT$363.58 Million | ▼ -65.6% |
| 2020 | 0.86x | NT$177.79 Million | NT$152.09 Million | ▼ -71.6% |
| 2019 | 3.01x | NT$231.77 Million | NT$697.33 Million | — |